Literature DB >> 21182135

Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Yasushi Itou1, Katsuyuki Nakanishi, Yoshifumi Narumi, Yasuko Nishizawa, Hideaki Tsukuma.   

Abstract

PURPOSE: To retrospectively evaluate the relationship between apparent diffusion coefficient (ADC) values and Gleason score (GS) in prostate cancer.
METHODS: A total of 60 patients who underwent radical prostatectomy for clinically localized prostate cancer were selected for this study. Diffusion-weighted magnetic resonance (MR) images were obtained using a 1.5 T system. ADC values were analyzed between three groups: GS of 6 or less (n = 7); GS of 7 (n = 37); and GS of 8 or higher (n = 16). ADC values of the three GS groups were statistically analyzed in order to determine the relationship with GS. In the 37 patients with GS = 7 the difference in ADC values between GS 3+4 and GS 4+3 was analyzed.
RESULTS: Median ADC values (10⁻³ mm² /s) of the three GS groups were 1.04 (GS = 6 or less), 0.867 (GS = 7), and 0.729 (GS = 8 or higher). Although there was considerable overlap among the groups, the differences in ADC were statistically significant (P < 0.0001). There was a significant inverse correlation between GS and ADC values (z = -0.437, P < 0.0005). Median ADC values (10⁻³ mm² /s) of GS 3+4 and GS 4+3 patients were 0.88 and 0.814, respectively (P < 0.05).
CONCLUSION: ADC values showed a negative correlation with GS. Pathologically, however, there was considerable intrasubject heterogeneity.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21182135     DOI: 10.1002/jmri.22317

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  35 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

Authors:  C Arsov; D Blondin; R Rabenalt; G Antoch; P Albers; M Quentin
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

3.  Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.

Authors:  Andreas M Hötker; Yousef Mazaheri; Ömer Aras; Junting Zheng; Chaya S Moskowitz; Tatsuo Gondo; Kazuhiro Matsumoto; Hedvig Hricak; Oguz Akin
Journal:  AJR Am J Roentgenol       Date:  2016-02-22       Impact factor: 3.959

4.  Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Authors:  Raphaele Renard Penna; Geraldine Cancel-Tassin; Eva Comperat; Pierre Mozer; Priscilla Léon; Justine Varinot; Morgan Roupret; Marc-Olivier Bitker; Olivier Lucidarme; Olivier Cussenot
Journal:  World J Urol       Date:  2016-02-22       Impact factor: 4.226

5.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

6.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

7.  Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Authors:  Lian-Ming Wu; Zi-Zhou Zhao; Xiao-Xi Chen; Qing Lu; Shi-Teng Suo; Qiang Liu; Jiani Hu; E Mark Haccke; Jian-Rong Xu
Journal:  Br J Radiol       Date:  2016-04-19       Impact factor: 3.039

Review 8.  The emerging role of diffusion-weighted MRI in prostate cancer management.

Authors:  Edward M Lawrence; Vincent J Gnanapragasam; Andrew N Priest; Evis Sala
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

9.  [Multiparametric prostate MRI for follow-up monitoring after radiation therapy].

Authors:  A M Weidner; D J Dinter; M Bohrer; M Sertdemir; D Hausmann; F Wenz; S O Schoenberg
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

Review 10.  Extraprostatic extension in prostate cancer: primer for radiologists.

Authors:  Alice C Shieh; Ezgi Guler; Vijayanadh Ojili; Raj Mohan Paspulati; Robin Elliott; Nikhil H Ramaiya; Sree Harsha Tirumani
Journal:  Abdom Radiol (NY)       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.